Publications by authors named "P Sriraman"
Article Synopsis
- The study analyzed the use of physical restraints among hospitalized adults in a healthcare network, identifying that 6.3% of hospitalizations involved restraint use, particularly higher in intensive care units (39% of ICU cases).
- Factors like age, male gender, and language barriers were linked to higher likelihoods of restraint use.
- The ICD-10 code for physical restraint was found to have very low sensitivity (1.5%) but extremely high specificity (99.99%) when compared to electronic health record documentation, indicating a major gap in accurately capturing restraint use.
CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRPα interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. In this first clinical, phase 1, dose-escalation and -expansion study (CC-90002-AML-001; NCT02641002), we evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). CC-90002 was administered in escalating doses of 0.
View Article and Find Full Text PDFArticle Synopsis
- β-Thalassemia is a genetic blood disorder that causes issues with hemoglobin production, leading to the need for regular blood transfusions and potential complications like iron overload.
- Luspatercept is the first approved therapy in the U.S. that helps improve anemia in adult patients with β-thalassemia who rely on these transfusions, showing effective dosage and reduced transfusion needs.
- Studies indicate that luspatercept has a favorable safety profile and its administration is based on body weight, making it a promising alternative therapy for managing β-thalassemia.
Article Synopsis
- Luspatercept is a fusion protein that helps improve late-stage red blood cell development and has been studied in 260 patients with anemia from myelodysplastic syndromes.
- The drug has predictable pharmacokinetics and its dosage varies from 0.125 to 1.75 mg/kg, with body weight being the main factor for determining the correct dose.
- The findings indicate that higher serum levels of luspatercept improve the chances of patients achieving transfusion independence and experiencing fewer severe side effects, supporting a dose range of 1.0 to 1.75 mg/kg for effective long-term treatment.
Article Synopsis
- The 2018 Workshop on Recent Issues in Bioanalysis was held in Philadelphia with over 900 attendees from various sectors, focusing on bioanalysis, biomarkers, and immunogenicity over five days.
- The workshop aimed to facilitate discussions on current topics in bioanalysis, including small- and large-molecule assays utilizing LCMS and other methods, and resulted in comprehensive recommendations outlined in a White Paper.
- The White Paper is divided into three parts, with Part 3 specifically addressing large molecule bioanalysis and related topics, while Parts 1 and 2 cover small molecules and hybrid approaches, respectively.